**To the Editor:**

One major risk factor for cutaneous melanoma is ultraviolet (UV) exposure. Intense intermittent UV exposure and childhood sunburn are linked epidemiologically with melanoma risk, and in mice neonatal UV exposure promotes development of cutaneous melanoma ([@R18]; [@R13]). Other evidence that UV contributes to melanomagenesis includes increased risk for populations with extensive intense sun exposure, as well as for fair-skinned (Fitzpatrick's skin type I--II) individuals and patients with xeroderma pigmentosum, who repair photoproducts very poorly ([@R9]; [@R14]).

We have previously shown that telomere homolog oligonucleotides (collectively called T-oligos), but not complementary or unrelated control oligonucleotides, have multiple anti-cancer effects ([@R6]; [@R20]; [@R10]). T-oligo treatment prior to UV irradiation accelerates the removal of major UV-induced cyclobutane pyrimidine dimers (CPDs) and 6-4-photoproducts in cultured cells from newborn and adult donors ([@R11]), murine skin in vivo ([@R12]; [@R2]), and human skin ex-vivo ([@R1]). T-oligos have also been shown to cause cell cycle arrest, followed in many malignant cell types by apoptosis ([@R20]; [@R10]). We have previously shown that treatment with T-oligos (specifically, thymidine dinucleotide - pTT) during chronic UV irradiation prevents development of SCC in hairless mice ([@R12]) and of BCC in Ptch-1^+/−^ mice ([@R2]). In these models, intermittent topical pTT application enhances DNA repair of CPDs and 8-oxo-2′-deoxyguanosine, decreases mutagenesis, and in tumor nodules increases apoptosis and decreases proliferation. pTT also strikingly reduces Cox-2 protein expression in UV-irradiated skin ([@R2]).

Many mutations associated with familial melanoma occur at the CDKN2A locus that encodes two distinct proteins, p16 INK4a and p14 ARF (p19 ARF in mice) ([@R3]). Several knockout (KO) and transgenic animal models have been developed to study p16- and p19-dependent molecular mechanisms of melanoma development. Of interest to modeling human melanomagenesis, when p19^ARF−/−^ mice expressing H-ras driven by a tyrosinase promoter (Tyr-Hras/p19KO mice) are UV irradiated on day 2 or 3 after birth, there is a significant increase in melanoma development during early adulthood ([@R13]). In this study we evaluated the effect of topical pTT treatment in this model.

Newborn mice were treated topically with a 100 µM solution of pTT (Midland Certified Reagent Company, Midland, TX) or the PG/DMSO vehicle alone on days 1 and 2, then UV irradiated on day 3 using FS40 sunlamps (10 mJ/cm^2^) as metered at 285±5mm, an irradiation protocol known to cause melanomas by week 21 in approximately half the mice ([@R13]).

pTT-treated mice began to develop melanomas during week 12, while vehicle-treated mice began to develop tumors during week 7; and by week 21, 71% vs 46% of the mice remained tumor free ([Fig. 1A](#F1){ref-type="fig"}). All mice were examined weekly and sacrificed if their tumors were ≥1 cm in diameter or the animals appeared to be in distress. As well, in each treatment group, 4 mice died during weeks 15--17 for unclear reasons without evidence of tumor. Excluding these mice,at the end of 21 weeks, 13 of 24 vehicle-treated mice had tumors and 9 (69% of tumor-bearing mice) had to be sacrificed early, beginning at 11 weeks; but only 7 of the remaining 24 pTT-treated mice developed tumors and only one (14% of tumor-bearing mice) had to be sacrificed early, at 16 weeks ([Fig. 1A, 1B](#F1){ref-type="fig"} and [Table](#T1){ref-type="table"}). Vehicle-treated mice had an average of 3 times as many tumors per mouse as pTT-treated mice at the end of 21 weeks (p\<0.01, ANOVA post-hoc analysis) ([Fig. 1C](#F1){ref-type="fig"}). Differences between the pTT and vehicle groups were significant beginning during week 12 and then each week through the end of the study as determined by SPSS multiple comparisons (p=0.001). At 21 weeks, vehicle--treated mice had an average tumor burden of 325±100.68 mm^3^ vs.27.34±12.72 mm^3^ (p\<0.001) for pTT-treated mice ([Fig. 1D](#F1){ref-type="fig"}), a \>90% reduction.

Tumor size and multiplicity for the mice that were sacrificed or died early were included in the calculations as unchanged up to the termination of the experiment on week 21. Hence their contribution to total tumor burden, as well as possibly tumor multiplicity in these mice, is understated, as tumors would have been expected to continue growing. All tumors on surviving animals continued to grow throughout the study, and new tumors continued to appear. Most of the tumors were poorly-differentiated with a spindle-cell morphology; and all harvested tumors stained positively for Mart-1 (data not shown), confirming that they were indeed melanomas, despite being amelanotic in these albino mice.

Our data demonstrate that topical pTT application to newborn melanoma-prone mice only twice prior to UV irradiation delays and reduces subsequent melanoma development. This effect is consistent with the previously documented ability of pTT to increase the rate and accuracy of UV-induced DNA damage repair when provided to cultured cells or to intact skin 24--48 hours prior to irradiation. One presumptive pTT target is the melanocytic stem cell that resides in the upper permanent portion of the hair follicle ([@R16]; [@R17]). These cells are understood to persist after the single irradiation on post-natal day 3 through multiple cycles of cell division and ultimately to give rise, weeks later, to a melanoma. Reducing the number of UV-induced melanocyte mutations, as shown to occur in pTT-treated epidermal keratinocytes in irradiated mouse skin ([@R12]; [@R2]), should logically reduce the number of Tyr-Hras/p19KO cells further predisposed to give rise to invasive melanoma. In addition, pTT effects on non-melanocytic cells may also have contributed to the \>90% reduction in melanoma burden. For example, pTT treatment presumably reduced epidermal expression of Cox-2, the UV-inducible pro-inflammatory enzyme that enhances development of keratinocytic malignancies in irradiated mouse skin ([@R8]; [@R19]) and whose protein expression is markedly reduced over at least several days by pTT ([@R2]; [@R15]). Cox-2 inhibitors have been shown in intervention studies to reduce UV-induced non-melanoma skin cancers ([@R7]) and more recently also melanomas (Curiel-Lewandrowski et al., 2011) in humans. Finally, pTT is known to have immunomodulatory effects ([@R5]; [@R4]) and may have modified interferon-mediated events recently shown to enhance melanomagenesis in mice following UV irradiation in the newborn period ([@R21]).

Of note, in human skin explants pTT treatment enhances epidermal pigmentation within 24 hours and this reduces initial UV-induced DNA damage by approximately 50% ([@R1]). This potentially additional photoprotective effect of pTT could not be observed in the albino mice used in these experiments.

Together, our findings further support a critical role for UV-induced damage in melanoma development and for photoprotection as a key preventive strategy.
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![Effect of pTT on melanomagenesis in UV-irradiated Tyr-Hras/p19KO mice over the 21 week study. Open symbols (rectangles): pTT-treated mice; black symbols (diamonds): vehicle-treated mice. **A**: Cumulative tumor free survival. Compared to vehicle, pTT markedly increased tumor-free survival (p\<0.04, SPSS multiple comparisons). Black circles indicate one or more mice dying for unknown reasons or euthanized because of large tumors, after which they are censored from the analysis. **B:** Survival analysis. Four mice in each group died for unknown reasons in weeks 15--17. All other mice died or were euthanized because of large tumors. Compared to the vehicle, pTT increased overall survival (p\<0.04, Kaplan Meier survival analysis) without affecting deaths from non-tumor related causes. **C**: Number of tumors per mouse (mean ± SD). Compared to the vehicle, pTT caused a marked decrease in the average number of tumors per mouse (p\<0.01). **D:** Total tumor burden (mm^3^) per mouse (mean ± SD), calculated using the formula volume=4/3 Pi (length/2) (width/2)^2^. Compared to vehicle, pTT caused a \>90% reduction in average total tumor volume (p = 0.001).](nihms371286f1){#F1}

###### 

Fate of Tyr-Hras/ p19KO Mice

  -------------------------------------------------------------------------------------------------
  Treatment\    Initial Number\   Mice Dying or Euthanized\   Live Mice at\   Mice with ≥ 1\   
  Group         of Mice           By Week 21                  Week 21         Tumor During\    
                                                                              Study            
  ------------- ----------------- --------------------------- --------------- ---------------- ----
  **Vehicle**   28                4                           9               15               13

  **pTT**       28                4                           1               23               6
  -------------------------------------------------------------------------------------------------
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